Viking Therapeutics (VKTX) Invested Capital (2014 - 2018)

Viking Therapeutics has reported Invested Capital for 4 years, with the latest figure at $1.9 million in Q1 2018.

• Quarterly Invested Capital fell 1.95% year-over-year to $1.9 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $1.9 million (down 75.24% YoY) and the FY2017 annual result came in at $1.9 million, down 1.95% from the prior year.
• Invested Capital held at $1.9 million in Q1 2018 per VKTX's latest filing, from $1.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $2.5 million in Q4 2015 and troughed at $1.9 million in Q3 2017.
• A 4-year average of $2.0 million and a median of $2.0 million in 2016 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2016 and 2017: Invested Capital fell 21.79% in 2016, then changed 0.0% in 2017.
• Over 4 years, Invested Capital stood at $2.5 million in 2015, then decreased by 21.79% to $2.0 million in 2016, then declined by 1.95% to $1.9 million in 2017, then changed by 0.0% to $1.9 million in 2018.
• According to Business Quant data, Invested Capital over the past three periods registered $1.9 million, $1.9 million, and $1.9 million for Q1 2018, Q4 2017, and Q3 2017 respectively.